Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01463111 · ClinicalTrials.gov registry record · NA

Decision-Making in Bipolar Disorder

A NA study, sponsored by Emory University.

Completed
Registry status
NA
Development phase
37
Enrollment target

NCT01463111 is a NA study that has completed, run by Emory University. The registered enrollment target is 37 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01463111, a NA study, has completed, sponsored by Emory University.

COMPLETED
Registry status
NA
Development phase
37 participants
Enrollment target

Study Summary

Forty subjects with bipolar disorder who are not receiving a mood-stabilizing medication for the treatment of their illness will participate in this study. The study aims to evaluate how decision-making is affected by treatment for bipolar disorder. Prior to beginning treatment, patients will complete questionnaires and a one-hour computer-administered assessment of decision-making. Differences between pre-post decision-making outcomes will be evaluated to examine whether the neuroeconomic concepts of risk aversion, loss aversion, risk tolerance and delay discounting are affected by treatment. The overall goal of this study will be to identify whether decision-making in people with bipolar disorder is affected by treatment. Specifically the investigators will compare decision-making characteristics among bipolar patients prior to treatment with how these decision-making characteristics change over the course of 6 weeks of standard medication therapy for bipolar disorder. A total of 6 decision-making tasks and one control task will be administered via computer to eligible subjects. The investigators will evaluate decision-making under varying conditions of reward, risk, and uncertainty and over time. The investigators hypothesize that decision-making will improve across these assessments after 6 weeks of treatment.

Interventions

  • DRUG Lamotrigine
  • DRUG Lithium
  • DRUG Valproate

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 2011-05
Est. Completion 2016-04
Phase NA

Sponsor

Emory University

1,208 total trials

What the Registry Record Tells You About NCT01463111

The ClinicalTrials.gov registry entry for NCT01463111 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Lamotrigine is the first listed.

NCT01463111 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01463111 about?

NCT01463111 is a clinical study titled "Decision-Making in Bipolar Disorder". Forty subjects with bipolar disorder who are not receiving a mood-stabilizing medication for the treatment of their illness will participate in this study. The study aims to evaluate how decision-making is affected by treatment for bipolar disorder. Prior to beginning treatment, patients will comple...

What is the current status of trial NCT01463111?

This trial is currently completed. It is a NA study. The enrollment target is 37 participants. The study started on 2011-05. Estimated completion is 2016-04.

What interventions are being tested in trial NCT01463111?

The interventions under investigation include: Lamotrigine (DRUG), Lithium (DRUG), Valproate (DRUG).

Who is sponsoring clinical trial NCT01463111?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.